

Public release date: 15-Apr-2010

Contact: Colleen Butz
cbutz@spectrums-science.com
001-202-251-2037
International Association for the Study of Lung Cancer

Discover why this is a critical moment for lung cancer research

Live webcast from the 2nd European Lung Cancer Conference

What: The International Association for the Study of Lung Cancer (IASLC) and the European Society for Medical Oncology (ESMO) will hold an educational seminar for members of the media highlighting the recent advances in personalized treatment for lung cancer, focusing on how the extent of disease, staging, histology and molecular testing contribute to the equation.



The diversity of the panel's expertise offers unique insight about the most pertinent advancements in lung cancer treatment. Embedded within the second European Lung Cancer Conference (ELCC), this distinct educational session is crafted specifically to suit the media perspective. The topics and key points of the presentations extract the vital insights that are imperative for the public at large. The session will be conducted at the ELCC and via Webcast to accommodate media participation worldwide.

Who: Moderated by Dr. Peter Goldstraw and Dr. Rafael Rosell, the IASLC and ESMO panel will feature the world's leading lung cancer experts discussing the four most prominent focuses of personalized therapy in lung cancer.

Experts and Topics:

- Dr. Peter Goldstraw: Consultant Thoracic Surgeon, Royal Brompton Hospital; Past-Chair, IASLC Staging Project. He will give an overview of how lung cancer staging classification has changed, and clinical implications.
- Dr. Paul Van Houtte: Head of the Department of Radiotherapy for the Institut Jules Bordet will discuss newer aspects of treatment planning to accurately target the anatomical extent of the disease.
- Dr. Rolf Stahel: Senior Staff Physician at the Clinic and Policlinic of Oncology, University Hospital of Zürich and Titular Professor of Medicine at the University of Zürich, Switzerland, will explain the impact of histology on customizing systemic therapy of lung cancer.
- Dr. Fortunato Ciardiello: Associate Professor of Medical Oncology and Chair of the ESMO Translational Research Working Group and member of the ESMO Educational Steering Committee. He will overview targeted therapy and perspectives of lung cancer molecular classification.

When: Thursday April 29 from 7:00 a.m. (EST) [13.00 to 14.00 CEST]

Where: Geneva Palexpo, 1218 Grand-Saconnex, Geneva, Switzerland: Room L

Webcast Details: In addition to a physical presence at the ELCC, the panel discussion will be broadcast over the Internet via Webcast. Webcast participants will be able to view the panelists' slides by

logging into the Webcast from their computers, and audio for the presentation can be accessed either from guests' computers or by dialing in using their telephones. During the Q&A session, participants will be able to ask questions by entering their request via the Webcast's chat feature or by alerting the telephone operator.

To access the Webcast, please see the following instructions:

| Step 1: Toll-free dial-In | Access Code: 5872511 |
|--|-----------------------------|
| US: (800) 747-5150 | |
| Belgium: 080039117 | |
| Switzerland: 0800700283 | |
| UK: 08004960577 | |
| Italy: 800182597 | |
| Spain: 900800371 | |
| France: 0800941632 | |
| Netherlands: 08002658213 | |
| China: 8008190299; 4006208033 | |
| Step 2: Web Login https://cc.callinfo.com/r/1v5ed6by4zr53 | |

For help joining the Webcast:
888-447-1119 [from U.S.]
303-389-4018 [International Help]
Email: iccc@gblix.net
Web: Conferencing Support

###
